

Ruth L Goodall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7478870/publications.pdf>

Version: 2024-02-01

30
papers

844
citations

566801

15
h-index

476904

29
g-index

32
all docs

32
docs citations

32
times ranked

1479
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 353-61.	3.8	146
2	Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 56-62.	1.1	140
3	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. <i>PLoS Medicine</i> , 2018, 15, e1002514.	3.9	98
4	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. <i>Vaccine</i> , 2008, 26, 3153-3161.	1.7	54
5	Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine+Lamivudine plus Nevirapine and Zidovudine+Lamivudine plus Abacavir. <i>Journal of Infectious Diseases</i> , 2010, 201, 106-113.	1.9	46
6	High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 1023-1026.	2.9	36
7	TIMING AND INTERPRETATION OF TESTS FOR DIAGNOSING PERINATALLY ACQUIRED HEPATITIS C VIRUS INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 715-716.	1.1	32
8	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002491.	3.9	29
9	Interval-censored survival time data: confidence intervals for the non-parametric survivor function. <i>Statistics in Medicine</i> , 2004, 23, 1131-1145.	0.8	27
10	Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1806-1809.	1.4	21
11	Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 277-283.	0.9	20
12	Bronchopulmonary Kaposi s sarcoma in 106 HIV 1 infected patients. <i>International Journal of STD and AIDS</i> , 1998, 9, 518-525.	0.5	17
13	A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. <i>PLoS ONE</i> , 2013, 8, e57580.	1.1	17
14	Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. <i>PLoS ONE</i> , 2015, 10, e0137834.	1.1	17
15	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. <i>PLoS ONE</i> , 2011, 6, e14764.	1.1	16
16	Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study. <i>Lancet HIV</i> , 2015, 2, e530-e539.	2.1	16
17	Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1032-1037.	0.5	15
18	Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1450-1455.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1215-1222.	0.5	14
20	High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study. <i>PLoS ONE</i> , 2017, 12, e0173243.	1.1	13
21	Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e151-e158.	2.1	12
22	High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial. <i>PLoS ONE</i> , 2014, 9, e90772.	1.1	9
23	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 404-415.	2.9	8
24	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25871.	1.2	8
25	Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25477.	1.2	5
26	The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. <i>BMC Infectious Diseases</i> , 2017, 17, 160.	1.3	3
27	Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 215-216.	0.9	2
28	Inpatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 749-756.	0.5	2
29	Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis. <i>Trials</i> , 2022, 23, .	0.7	2
30	Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial. <i>HIV Clinical Trials</i> , 2009, 10, 385-393.	2.0	1